Strategic Signals Weekly

Replimune Group, Inc. announced receipt of a second Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec). The BLA sought approval for RP1 in combination with nivolumab for the treatment of advanced melanoma.

Drug: RP1 (vusolimogene oderparepvec) · Indication: advanced melanoma

MeiraGTx Holdings plc acquired Janssen Pharmaceuticals, Inc.'s gene therapy product, botaretigene sparoparvovec (RPGR Product), for X-linked retinitis pigmentosa, including the underlying license agreement with UCL Business Plc. The deal involved an upfront cash payment of $25 million, with additional contingent milestones and royalties. MeiraGTx also provided an update on clinical data for botaretigene sparoparvovec, which showed positive trends in functional vision and statistically significant improvements in other visual endpoints, despite the primary endpoint not meeting statistical significance.

Drug: botaretigene sparoparvovec · Indication: X-linked retinitis pigmentosa related to mutations in the RPGR gene · Partner: Janssen Pharmaceuticals, Inc.

Trevi Therapeutics, Inc. priced an underwritten public offering of common stock, expecting net proceeds of approximately $141.1 million, which will extend its cash runway through 2029. These funds are earmarked to advance Haduvio's development, including two planned Phase 3 trials for chronic cough in IPF patients and Phase 2b trials for non-IPF ILD-related and refractory chronic cough, with topline results anticipated from 2027 to 2028.

Revolution Medicines, Inc. issued $500 million aggregate principal amount of 0.50% Convertible Senior Notes due 2033. These notes are senior, unsecured obligations and are convertible into cash, common stock, or a combination, at the company's election, with an initial conversion price of approximately $198.80 per share. The notes mature on May 1, 2033, unless earlier repurchased, redeemed, or converted.

Revolution Medicines, Inc. completed an equity offering, selling 10,563,381 shares at $142.00 per share, with underwriters fully exercising their option for an additional 1,584,506 shares. This transaction is expected to generate approximately $1,650.4 million in net proceeds for the company. Concurrently, the company is also undertaking a $500 million convertible senior notes offering.

MeiraGTx Holdings plc entered into an underwriting agreement with BofA Securities, Inc. and Goldman Sachs & Co. LLC for a public offering of 11,111,111 ordinary shares at $9.00 per share. The company expects to receive net proceeds of approximately $93.3 million, which it plans to use for general corporate purposes, including working capital and capital expenditures. This financing is anticipated to fund operations into the second half of 2028, supporting potential commercial launches of bota-vec for X-linked retinitis pigmentosa and AAV-hAQP1 for radiation-induced xerostomia, if approved.

Achieve Life Sciences, Inc. completed a private placement, raising approximately $180.0 million in gross proceeds from institutional and accredited investors through the sale of common stock and warrants. The company intends to use these funds to support a Phase 3 clinical trial for cytisinicline in e-cigarette cessation, commercialization efforts, and general corporate purposes. Concurrently, Richard Stewart stepped down as CEO, with Andrew Goldberg appointed as his successor.